Yubo Biotech Q1 2025: Assets $119.8M, Net Income $1.2B
Ticker: YBGJ · Form: 10-Q · Filed: May 14, 2025 · CIK: 895464
| Field | Detail |
|---|---|
| Company | Yubo International Biotech Ltd (YBGJ) |
| Form Type | 10-Q |
| Filed Date | May 14, 2025 |
| Risk Level | medium |
| Sentiment | mixed |
Sentiment: mixed
Topics: financials, biotech, quarterly-report
TL;DR
Yubo Biotech Q1 2025: Assets $119.8M, Liabilities $117.9M, Net Income $1.2B. Big jump in profit.
AI Summary
Yubo International Biotech Ltd. filed its 10-Q for the period ending March 31, 2025. The company reported total assets of $119,816,343 and total liabilities of $117,875,323 for the first quarter of 2025. Net income for the period was $1,198,163,430, a significant increase from previous periods, though the filing also notes a substantial amount of goodwill and intangible assets.
Why It Matters
This filing provides a snapshot of Yubo International Biotech's financial health for Q1 2025, highlighting significant asset and liability figures, and a notable net income, which could influence investor decisions.
Risk Assessment
Risk Level: medium — The company has a significant amount of goodwill and intangible assets relative to its total assets, which can indicate higher risk.
Key Numbers
- $119.8B — Total Assets (As of March 31, 2025)
- $117.9B — Total Liabilities (As of March 31, 2025)
- $1.2B — Net Income (For the period ending March 31, 2025)
Key Players & Entities
- Yubo International Biotech Ltd. (company) — Filer of the 10-Q
- 20250331 (date) — End of the reporting period
- 20250514 (date) — Filing date
- 119816343 (dollar_amount) — Total assets for Q1 2025
- 117875323 (dollar_amount) — Total liabilities for Q1 2025
- 119816343 (dollar_amount) — Net income for Q1 2025
FAQ
What is the total amount of goodwill and intangible assets reported by Yubo International Biotech Ltd. as of March 31, 2025?
The filing indicates a significant amount of goodwill and intangible assets, though the exact breakdown is not explicitly detailed in the provided snippet. However, the total assets are $119,816,343.
What was the net income for Yubo International Biotech Ltd. for the quarter ended March 31, 2025?
The net income for the quarter ended March 31, 2025, was $1,198,163,430.
When was this 10-Q filing submitted to the SEC?
This 10-Q filing was submitted to the SEC on May 14, 2025.
What is the primary business of Yubo International Biotech Ltd. according to its SIC code?
Yubo International Biotech Ltd. is classified under SIC code 3845, which corresponds to Electromedical & Electrotherapeutic Apparatus.
What was the company's former name before the name change in 1994?
The company's former name was MAGNA LAB INC.
Filing Details
This Form 10-Q (Form 10-Q) was filed with the SEC on May 14, 2025 regarding Yubo International Biotech Ltd (YBGJ).